Marcel Verheij, PhD, and John Marshall, MD, on Gastric Cancer: First Results From the CRITICS Trial
2016 ASCO Annual Meeting
Marcel Verheij, PhD, of the Netherlands Cancer Institute, and John Marshall, MD, of Georgetown University Lombardi Comprehensive Cancer Center, discuss findings from this multicenter phase III study of neoadjuvant chemotherapy followed by either surgery and chemotherapy or surgery and chemoradiotherapy in resectable gastric cancer (Abstract 4000).
Heinz-Josef Lenz, MD, of the University of Southern California, and Jonathan R. Strosberg, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discuss efficacy and safety results in patients with midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 4005).
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).
Newly elected ASCO President Daniel F. Hayes, MD, of the University of Michigan Health System Comprehensive Cancer Center, talks about his vision for the society during his tenure.
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuss findings on BGJ398 in patients with previously treated advanced/metastatic urothelial carcinoma with FGFR3 alterations (Abstract 4517).
The
Jonathan A. Ledermann, MD, of Cancer Research UK and University College London Cancer Trials Centre, and Ursula A. Matulonis, MD, of the Dana-Farber Cancer Institute, discuss findings on overall survival in patients with platinum-sensitive relapsed serous ovarian cancer receiving olaparib maintenance monotherapy (Abstract 5501).
